Back

The M1 aminopeptidase NPEPPS is a novel regulator of cisplatin sensitivity

Jones, R. T.; Goodspeed, A.; Akbarzadeh, M. C.; Scholtes, M.; Vekony, H.; Jean, A.; Tilton, C. B.; Orman, M. V.; Joshi, M.; Laajala, T. D.; Javaid, M.; Clambey, E. T.; Layer, R.; Parker, S.; Zuiverloon, T.; Theodorescu, D.; Costello, J. C.

2021-03-04 cancer biology
10.1101/2021.03.04.433676 bioRxiv
Show abstract

There is an unmet need to improve efficacy of platinum-based cancer chemotherapy. Using multi-omic assessment of cisplatin-responsive and -resistant human bladder cancer cell lines and whole-genome CRISPR screens, we identified Puromycin-Sensitive Aminopeptidase, NPEPPS, as a novel driver of cisplatin resistance. NPEPPS depletion sensitizes resistant bladder cancer cells to cisplatin in vitro and in vivo. Conversely, overexpression of NPEPPS in sensitive cells increased cisplatin resistance. We show that NPEPPS affects treatment response by regulating intracellular cisplatin concentrations. Patient-derived organoids (PDOs) generated from bladder cancer samples before and after cisplatin-based treatment, and from patients who did not receive cisplatin, were evaluated for sensitivity to cisplatin and they were found to be concordant with clinical response. In PDOs, shRNA depletion or pharmacologic inhibition of NPEPPS led to increased cisplatin sensitivity, while NPEPPS overexpression had the opposite effect. Our data present NPEPPS as a novel and druggable driver of cisplatin resistance by regulating intracellular cisplatin concentrations, along with providing the preclinical data to support clinical trials combining NPEPPS inhibition with cisplatin.

Matching journals

The top 8 journals account for 50% of the predicted probability mass.

1
eLife
● 5828 papers in training set
Top 6%
12.9%
Similar papers in this journal
2
Cell Reports
○ 1498 papers in training set
Top 4%
6.7%
Similar papers in this journal
3
Cancer Research
● 130 papers in training set
Top 0.5%
6.3%
Similar papers in this journal
4
Molecular Systems Biology
○ 162 papers in training set
Top 0.3%
5.5%
Similar papers in this journal
5
Nature Communications
○ 5641 papers in training set
Top 26%
5.5%
Similar papers in this journal
6
Cancer Research Communications
● 51 papers in training set
Top 0.1%
5.5%
7
Science Advances
● 1243 papers in training set
Top 5%
5.2%
8
Cancer Cell
○ 42 papers in training set
Top 0.3%
4.0%
50% of probability mass above
9
Life Science Alliance
● 285 papers in training set
Top 1%
3.2%
10
NAR Cancer
◐ 37 papers in training set
Top 0.2%
2.4%
11
Communications Biology
○ 993 papers in training set
Top 9%
2.4%
12
Cell
○ 431 papers in training set
Top 5%
2.1%
13
Cell Reports Medicine
○ 153 papers in training set
Top 2%
2.1%
14
The EMBO Journal
○ 309 papers in training set
Top 3%
1.9%
15
Proceedings of the National Academy of Sciences
● 2444 papers in training set
Top 25%
1.9%
16
EMBO Reports
○ 263 papers in training set
Top 3%
1.7%
17
EMBO Molecular Medicine
○ 95 papers in training set
Top 0.8%
1.7%
18
British Journal of Cancer
○ 49 papers in training set
Top 0.7%
1.7%
19
Cancer Discovery
● 66 papers in training set
Top 1%
1.7%
20
Nucleic Acids Research
◐ 1281 papers in training set
Top 9%
1.5%
21
Genome Biology
○ 637 papers in training set
Top 6%
1.4%
22
iScience
○ 1154 papers in training set
Top 23%
1.3%
23
Molecular Cell
○ 350 papers in training set
Top 4%
1.1%
24
Cell Systems
○ 201 papers in training set
Top 4%
1.0%
25
Cell Genomics
○ 172 papers in training set
Top 4%
0.8%
26
Cancers
○ 213 papers in training set
Top 5%
0.8%
27
JCI Insight
● 277 papers in training set
Top 9%
0.6%
28
Molecular Oncology
○ 55 papers in training set
Top 2%
0.6%
29
Molecular Cancer Research
● 49 papers in training set
Top 2%
0.6%
30
Cancer Letters
○ 35 papers in training set
Top 1%
0.6%

"Similar papers" are the closest papers from that journal in the model's embedding space. They show what the match is built on, but the ranking comes mostly from a classifier over the whole training set, not from these examples alone.